Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction

Molecular Biology of the Cell

Volumn 23, Issue 4, 2012, Pages 567-576

  Orth, James D ^a   Loewer, Alexander ^a,b   Lahav, Galit ^a   Mitchison, Timothy J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE ACTIVATED DEOXYRIBONUCLEASE; CASPASE INHIBITOR; CYTOCHROME C; DNA; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; DNA DAMAGE; HUMAN; HUMAN CELL; MITOCHONDRION; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMITOTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DEOXYRIBONUCLEASES; DNA DAMAGE; HUMANS; KINESIN; MITOSIS; QUINOLINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855391980     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E11-09-0781     Document Type: Article

References (56)

1. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R (2001). Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20, 147-155. (Pubitemid 32150260)
2. Barboule N, Chadebech P, Baldin V, Vidal S, Valette A (1997). Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 15, 2867-2875. (Pubitemid 28004576)
3. Batchelor E, Loewer A, Lahav G (2009). The ups and downs of p53: understanding protein dynamics in single cells. Nat Rev Cancer 9, 371-377.
4. Batchelor E, Loewer A, Mock C, Lahav G (2011). Stimulus-dependent dynamics of p53 in single cells. Mol Syst Biol 7, 488.
5. Batchelor E, Mock CS, Bhan I, Loewer A, Lahav G (2008). Recurrent initiation: a mechanism for triggering p53 pulses in response to DNA damage. Mol Cell 30, 277-289. (Pubitemid 351615316)
6. Betti CJ, Villalobos MJ, Jiang Q, Cline E, Diaz MO, Loredo G, Vaughan AT (2005). Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity. Leukemia 19, 2289-2295. (Pubitemid 41741626)
7. Blagosklonny MV (2006). Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis. Cell Cycle 5, 971-975.
8. Blagosklonny MV (2007). Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 6, 70-74.
9. Borel F, Lohez OD, Lacroix FB, Margolis RL (2002). Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. Proc Natl Acad Sci USA 99, 9819-9824. (Pubitemid 34831131)
10. Borghaei H et al. (2008). Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol 3, 1286-1292.
11. Brito DA, Rieder CL (2006). Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 16, 1194-1200. (Pubitemid 43867292)
12. Chan YW, On KF, Chan WM, Wong W, Siu HO, Hau PM, Poon RY (2008). The kinetics of p53 activation versus cyclin E accumulation underlies the relationship between the spindle-assembly checkpoint and the postmitotic checkpoint. J Biol Chem 283, 15716-15723.
13. Dalton WB, Nandan MO, Moore RT, Yang VW (2007). Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res 67, 11487-11492.
14. Dayton MA, Nahreini P, Srivastava A (1989). Augmented nuclease activity during cellular senescence in vitro. J Cell Biochem 39, 75-85. (Pubitemid 19052857)
15. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL (1997). Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 94, 4000-4004. (Pubitemid 27180488)
16. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S (1998). A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391, 43-50. (Pubitemid 28079208)
17. Gascoigne KE, Taylor SS (2008). Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14, 111-122.
18. Gasser S, Orsulic S, Brown EJ, Raulet DH (2005). The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186-1190. (Pubitemid 41232299)
19. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR (2000). The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2, 156-162.
20. Hars ES, Lyu YL, Lin CP, Liu LF (2006). Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment-related acute myelogenous leukemia. Cancer Res 66, 8975-8979. (Pubitemid 44521114)
21. Hu CK, Coughlin M, Field CM, Mitchison TJ (2008). Cell polarization during monopolar cytokinesis. J Cell Biol 181, 195-202. (Pubitemid 351574546)
22. Huang HC, Shi J, Orth JD, Mitchison TJ (2009). Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16, 347-358.
23. Inuzuka H et al. (2011). SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471, 104-109.
24. Jin S, Levine AJ (2001). The p53 functional circuit. J Cell Sci 114, 4139-4140. (Pubitemid 33138651)
25. Lai SK, Wong CH, Lee YP, Li HY (2011). Caspase-3-mediated degradation of condensin Cap-H regulates mitotic cell death. Cell Death Differ 18, 996-1004.
26. Lanni JS, Jacks T (1998). Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18, 1055-1064. (Pubitemid 28063440)
27. Larsen BD, Rampalli S, Burns LE, Brunette S, Dilworth FJ, Megeney LA (2010). Caspase 3/caspase-activated DNase promote cell differentiation by inducing DNA strand breaks. Proc Natl Acad Sci USA 107, 4230-4235.
28. Lo Celso C, Fleming HE, Wu JW, Zhao CX, Miake-Lye S, Fujisaki J, Cote D, Rowe DW, Lin CP, Scadden DT (2009). Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 457, 92-96.
29. Loewer A, Batchelor E, Gaglia G, Lahav G (2010). Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells. Cell 142, 89-100.
30. Lovric MM, Hawkins CJ (2010). TRAIL treatment provokes mutations in surviving cells. Oncogene 29, 5048-5060.
31. Margolis RL, Lohez OD, Andreassen PR (2003). G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 88, 673-683. (Pubitemid 36258817)
32. Meek DW (2000). The role of p53 in the response to mitotic spindle damage. Pathol Biol (Paris) 48, 246-254.
33. Morris EJ, Keramaris E, Rideout HJ, Slack RS, Dyson NJ, Stefanis L, Park DS (2001). Cyclin-dependent kinases and P53 pathways are activated independently and mediate Bax activation in neurons after DNA damage. J Neurosci 21, 5017-5026. (Pubitemid 32622927)
34. Nakai R et al. (2009). K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res 69, 3901-3909.
35. Orth JD, Kohler RH, Foijer F, Sorger PK, Weissleder R, Mitchison TJ (2011). Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res 71, 4608-4616.
36. Orth JD, Tang Y, Shi J, Loy CT, Amendt C, Wilm C, Zenke FT, Mitchison TJ (2008). Quantitative live imaging of cancer and normal cells treated with kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther 7, 3480-3489.
37. Quignon F, Rozier L, Lachages AM, Bieth A, Simili M, Debatisse M (2007). Sustained mitotic block elicits DNA breaks: one-step alteration of ploidy and chromosome integrity in mammalian cells. Oncogene 26, 165-172. (Pubitemid 46095728)
38. Rieder CL, Maiato H (2004). Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 7, 637-651. (Pubitemid 39462685)
39. Sakahira H, Enari M, Nagata S (1998). Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391, 96-99. (Pubitemid 28079223)
40. Sanchez-Prieto R, Rojas JM, Taya Y, Gutkind JS (2000). A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 60, 2464-2472. (Pubitemid 30262438)
41. Schiemann K, Finsinger D, Zenke F, Amendt C, Knochel T, Bruge D, Buchstaller HP, Emde U, Stahle W, Anzali S (2010). The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5. Bioorg Med Chem Lett 20, 1491-1495.
42. Sherman WH, Fine RL (2001). Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 60, 316-321. (Pubitemid 32623446)
43. Shi J, Orth JD, Mitchison T (2008). Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 68, 3269-3276.
44. Shi J, Zhou Y, Huang HC, Mitchison TJ (2011). Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res.
45. Shieh SY, Ikeda M, Taya Y, Prives C (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334. (Pubitemid 27467963)
46. Stewart ZA, Tang LJ, Pietenpol JA (2001). Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 20, 113-124. (Pubitemid 32142344)
47. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA (2004). ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 64, 2390-2396. (Pubitemid 38523891)
48. Tan N, Malek M, Zha J, Yue P, Kassees R, Berry L, Fairbrother WJ, Sampath D, Belmont LD (2011). Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res 17, 1394-1404.
49. Tao W, South VJ, Diehl RE, Davide JP, Sepp-Lorenzino L, Fraley ME, Arrington KL, Lobell RB (2007). An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell Biol 27, 689-698. (Pubitemid 46080134)
50. Uetake Y, Sluder G (2004). Cell cycle progression after cleavage failure: mammalian somatic cells do not possess a "tetraploidy checkpoint." J Cell Biol 165, 609-615. (Pubitemid 38765762)
51. Uetake Y, Sluder G (2010). Prolonged prometaphase blocks daughter cell proliferation despite normal completion of mitosis. Curr Biol 20, 1666-1671.
52. Vassilev LT (2006). Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK1. Cell Cycle 5, 2555-2556.
53. Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, Heimbrook DC, Chen L (2006). Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA 103, 10660-10665. (Pubitemid 44078033)
54. Wertz IE et al. (2011). Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110-114.
55. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660. (Pubitemid 46232886)
56. Zhang XP, Liu F, Wang W (2011). Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci USA 108, 8990-8995.